Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug

This publication has 25 references indexed in Scilit:

• The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts
  European Journal Of Cancer, 1998
• Different Roles for Plasminogen Activators and Metalloproteinases in Melanoma Metastasis
  Published by Springer Nature ,1996
• Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours
  Archives of Dermatological Research, 1995
• The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts
  British Journal of Cancer, 1992
• A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells
  Melanoma Research, 1992
• Cathepsin B: association with plasma membrane in metastatic tumors.
  Proceedings of the National Academy of Sciences, 1986
• Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice
  Cancer Chemotherapy and Pharmacology, 1982
• A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
  Proceedings of the National Academy of Sciences, 1982
• Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion
  Journal of Medicinal Chemistry, 1980
• Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity of L1210 leukemic cells in vitro and in vivo
  Journal of Medicinal Chemistry, 1980